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Abstract
Background: Women with Down syndrome very rarely develop breast cancer even though they
now live to an age when it normally occurs. This may be related to the fact that Down syndrome
persons have an additional copy of chromosome 21 where the gene that codes for the
antiangiogenic protein Endostatin is located. Can this information lead to a primary antiangiogenic
therapy for early stage breast cancer that indefinitely prolongs remission? A key question that arises
is when is the initial angiogenic switch thrown in micrometastases? We have conjectured that
avascular micrometastases are dormant and relatively stable if undisturbed but that for some
patients angiogenesis is precipitated by surgery. We also proposed that angiogenesis of
micrometastases very rarely occurs before surgical removal of the primary tumor. If that is so, it
seems possible that we could suggest a primary antiangiogenic therapy but the problem then arises
that starting a therapy before surgery would interfere with wound healing.
Results: The therapy must be initiated at least one day prior to surgical removal of the primary
tumor and kept at a Down syndrome level perhaps indefinitely. That means the drug must have
virtually no toxicity and not interfere meaningfully with wound healing. This specifically excludes
drugs that significantly inhibit the VEGF pathway since that is important for wound healing and
because these agents have some toxicity. Endostatin is apparently non-toxic and does not
significantly interfere with wound healing since Down syndrome patients have no abnormal wound
healing problems.
Conclusion: We propose a therapy for early stage breast cancer consisting of Endostatin at or
above Down syndrome levels starting at least one day before surgery and continuing at that level.
This should prevent micrometastatic angiogenesis resulting from surgery or at any time later.
Adjuvant chemotherapy or hormone therapy should not be necessary. This can be continued
indefinitely since there is no acquired resistance that develops, as happens in most cancer therapies.
Background
While the mortality rate has been dropping in recent
years, breast cancer is diagnosed in 180,000 women and
men and kills over 40,000 yearly in the US [1]. When
breast cancer is first diagnosed, the patient is given a work-
up to determine if there is any evidence of distant metas-
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tases. If there is no overt sign of distant metastases, the
stage is considered early. If there is evidence of distant
metastases at diagnosis or at any time later in the disease
process, the stage is called late. Over 90% of new cases of
breast cancer are diagnosed at an early stage.
There is determined effort to detect breast cancer at the
earliest possible time since outcome after just surgery is
more often favorable than it is compared to detection
later. For example, women whose primary tumor is 1 cm
in size and without axillary lymph nodes involved with
cancer can expect 90% probability of cure after only
removal of the primary tumor. On the other hand, a
patient with 5 cm tumor and 10 lymph nodes with cancer
can expect only 10% probability of cure with simple sur-
gical removal of the primary tumor. Patients rarely die
from the primary tumor but from later distant relapse of
the cancer.
After surgery to remove the primary tumor, adjuvant ther-
apy is often administered to help prevent or delay any
possible appearance of distant metastases in the next 15–
20 years. It may be in the form of cytotoxic chemotherapy
or less toxic hormone therapy. There are well-established
means and guidelines to determine which if either or both
of these therapies is indicated for any particular patient.
However, treatment for early stage breast cancer too often
ultimately fails in that metastatic disease is discovered
within 15 or so years after initial diagnosis. Adjuvant
chemotherapy improves absolute cure rates by up to 15%.
Hormone therapy has approximately the same level of
benefit.
Treatment for metastatic disease is still mainly palliative
in that long term survival is rare. The median duration of
survival after relapse from early stage breast cancer is two
years. There is an urgent need for improved treatments for
early stage breast cancer that are far more effective in pre-
venting relapses for long periods of time – hopefully until
the person dies of another disease or old age. Based on the
experience over the past few decades, we are more likely to
make an impact by learning how to more effectively pro-
long remission in early stage breast cancer than we are in
learning how to eradicate a tumor that is macroscopic in
size.
Based on our computer simulations of clinical data, when
a person is diagnosed with early stage breast cancer, it is
rare that any sites of metastatic disease deposits have
achieved angiogenesis. That is, at the time of detection,
other than the primary tumor, there are usually only dis-
seminated distant dormant single cancer cells and distant
dormant avascular deposits present [2,3]. In human
breast cancer, single dormant cells have been proven but
(more difficult to observe) dormant avascular microme-
tastases have not yet been visualized [4].
A surprising finding from our analysis was that the surgery
to remove the primary tumor apparently often kick-starts
growth of the dormant cells and avascular micrometas-
tases. Most relapses occur within the first 5 years after sur-
gery and are mainly events that are triggered into growth
from surgery. We have suggested that one of the side
effects of surgery is to stimulate division of dormant single
malignant cells and stimulate angiogenesis of dormant
micrometastases. The latter is most apparent for the pre-
menopausal node-positive population. According to
these reports, 20% of premenopausal node-positive
patients undergo surgery-induced angiogenesis and over
half of all relapses in breast cancer are accelerated by sur-
gery [5]. There is no direct evidence that this quantitative
prediction is correct but there is strong indirect evidence
mainly from mammography data that it is valid and
numerically accurate [6-9]. For example, our analysis pre-
dicted that in trials of early detection conducted before the
routine use of adjuvant therapy, there would be 0.1 excess
deaths per 1000 screened premenopausal women in the
second or third year after the start of screening. This is con-
sistent with data based on 1.6 million person-years of fol-
low-up from mammography trials conducted in different
decades and in different countries. Surgery-induced ang-
iogenesis for premenopausal patients with positive nodes
is similar to the O'Reilly et al Lewis lung study [10].
These surgery-induced effects reduce the benefit of early
detection. Most persons derive benefit from early detec-
tion since they will be diagnosed with less extensive dis-
ease but paradoxically other persons will relapse and die
earlier as an unfortunate consequence of early detection.
This counterintuitive effect is most apparent in young
women.
Our more recent work suggests that this can partially
explain the excess breast cancer mortality of African-Amer-
icans, since the average age of diagnosis of African-Ameri-
cans is 46 years compared to 57 years for European-
Americans. This excess first appeared in the 1970s when
mammography began [11,12].
Perhaps not coincidentally, adjuvant chemotherapy
works best by far for premenopausal patients who are
node-positive. According to our theories, the reason for
this is that sudden metastatic tumor growth just after sur-
gery produces a chemosensitive window just at the time
when adjuvant therapy was empirically found to be most
effective. The implication is that surgery produces a dis-
ruption and acceleration of disease and then adjuvant
chemotherapy is used to address the effects of the disrup-
tion [13].BMC Cancer 2009, 9:7 http://www.biomedcentral.com/1471-2407/9/7
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In 2005 we analyzed data from an adjuvant hormone
therapy trial comparing Tamoxifen and Arimidex [14]. As
we reported, hormone therapy mainly suppresses relapses
that would have occurred in the first 5 years after surgery.
Other information along those lines is that Tamoxifen,
the most frequently used hormone therapy drug, is useful
in the first five years after surgery. After that time,
Tamoxifen has not been demonstrated to be of value. One
way of interpreting these data is that adjuvant hormone
therapy, like adjuvant chemotherapy, functions to coun-
teract surgery-induced growth of micrometastatic disease.
Working on the assumption that this is all true, we have
proposed that antiangiogenic drugs given when disease is
still microscopic would be very helpful but that this treat-
ment should be initiated before surgery since it is far more
difficult to reverse angiogenesis after it is established than
it is to prevent it from happening before it occurs [15].
Naumov et al suggest that if surgery induces angiogenesis
of dormant micrometastases, antiangiogenic, anti-inflam-
matory or other growth inhibiting drugs administered
before and/or after surgery might reduce relapse within 18
months of surgery [16].
The undisturbed half-life of avascular micrometastases in
breast cancer is 2 years and the undisturbed half-life of
single dormant cells is 1 year [2]. This suggests that the
avascular dormant state is the more stable of the two dor-
mant states. Efforts to prolong the natural tendency of
dormancy of disease in these early states, especially the
pre-angiogenic state, could be pursued as one method of
cancer control that would surely reduce cancer mortality.
Administering an antiangiogenic drug around the time of
surgery presents a conundrum since wound healing after
surgery highly depends on angiogenesis to remodel and
rebuild tissue [17]. So it would appear that starting an
antiangiogenic therapy before surgery and continuing it to
prevent micrometastases from escaping dormancy would
interfere with wound healing after primary tumor
removal. This seems to preclude using an antiangiogenic
therapy around the time of surgery. It would be very
important if a way could be found to treat early stage
breast cancer with an effective antiangiogenic drug for an
indefinite time starting before primary surgery but yet not
interfere with wound healing resulting from the surgery. Is
there any possible way around this apparent impasse?
Presentation of hypothesis
Down syndrome and the possible role of trisomy 21 in 
antiangiogenesis
Endostatin is the C-terminus fragment of collagen XVIII
(blood clotting function) and is a very robust inhibitor of
angiogenesis. The mechanism is thought to be an inhibi-
tion of endothelial cell migration and also apoptosis. It is
endogenous and non-toxic. In fact, unique in the history
of the FDA testing program, it has never been shown to
exhibit toxicity at any level at any concentration. It has, in
fact, been suggested that Endostatin be given to healthy
persons to diminish cancer as a public health concern [18-
20].
In support of that argument, Folkman and Kalluri [18]
have pointed out that persons with Down syndrome (DS)
rarely have breast cancer (10 – 25 fold less than age-
matched normals) and that they also have an elevated
level of Endostatin [20-22]. This is correlated to the
genetic defect in that DS persons have between two and
three copies of chromosome 21 which harbors the
Endostatin gene.
According to Greene et al [23] there are at least 283 pro-
tein encoding genes in chromosome 21, which corre-
sponds to approximately 1% of the human DNA. This
chromosomal defect responsible for the DS phenotype
also codes for collagen XVIII so, on average, DS persons
have more Endostatin than those with normal chromo-
some 21. The ratio is approximately 1.8 according to Zor-
ick et al [20] and 1.48 according to Greene et al [23].
One possible explanation for the lack of breast cancer in
DS is the high level of Endostatin resulting from trisomy
21. As another explanation, since collagen XVIII is a major
component of the basal membrane of tumor-associated
blood vessels, perhaps its uncontrolled expression is
responsible for a relative defect in tumor angiogenesis in
DS.
DS often have congenital heart disease that is repairable
with surgery so there are data on wound healing. Lange et
al reported on results of surgery to repair complete atriov-
entricular septal defect in 476 patients, 71.6% of who
were DS and the remainder normal [24]. There was 30 day
mortality of 4.9% in the DS and 5.6% in those with nor-
mal chromosomes. There was more frequent pulmonary
hypertension among DS but there was no difference in
operational strategy or timing of repair. It was concluded
that the presence of DS was not a risk factor for surgical
repair of complete atrioventricular septal defect. While
this might suggest Endostatin has no antiangiogenic activ-
ity, we think a better explanation is that Endostatin at the
DS level does not adversely affect wound healing.
Endostatin was patented December 29, 1998. This drug
has not lived up to the very high initial expectations of
benefit. Phase I and Phase II clinical trials were conducted
following the highest standard of clinical trial methodol-
ogy and translational research [25-28] however these tri-
als failed to show any significant anti-tumor activity or
abnormalities of wound healing or in tumor angiogen-BMC Cancer 2009, 9:7 http://www.biomedcentral.com/1471-2407/9/7
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esis. This is in contrast to the positive results from trials of
other antiangiogenic compounds Bevacizumab and
Sunitinib. However, Endostatin has occasionally and dra-
matically stabilized disease in a few otherwise hopeless
cases. In addition, the original Boehm et al [29] results of
Endostatin in animal models have not been reproduced.
Overall, it is fair to say that previous efforts to induce
tumor dormancy with continuous high levels of Endosta-
tin have produced mixed results [30-32].
From our perspective, Endostatin would be more effective
to prevent angiogenesis before it happens in breast cancer,
a disease with an apparent strong tendency to remain dor-
mant at least prior to primary tumor removal. The previ-
ous use of continuous high levels of Endostatin did not
work well, perhaps because it was started too late in the
disease life cycle (after angiogenesis had already hap-
pened). We think that studies using early stage breast can-
cer may be more likely to be beneficial.
A molecule very similar to Endostatin called Endostar has
been manufactured in significant quantities by a company
in China. This drug has been tested in the Folkman lab
and found to be twice as effective as early samples of
Endostatin. [Recent developments have improved
Endostatin half-life from hours to weeks [33].] Endostar is
currently used in China for late stage lung cancer patients
but is not currently approved for use in the US. No clinical
data have been published yet in a peer review journal.
According to Xu et al, Endostatin can maintain tumors in
a state of dormancy although they report that the half-life
is short so Endostatin is best utilized with prolonged
delivery using mini-osmotic pumps or cell encapsulations
systems [34]. They also report results are best when the
drug is administered as early as possible and no evidence
of drug resistance has been seen.
It has been suggested that 1.6 or 1.7 fold increase of
Endostatin relative to average normal level will prevent
angiogenesis. Zorick et al, however, have suggested that
only 30% more Endostatin than normal will effectively
prevent angiogenesis [20]. There might be no acquired
resistance to this therapy judging by the DS data. That is
important since it is widely accepted that conventional
chemotherapy and hormone therapy drugs eventually
cease to be effective due to acquired drug resistance.
Zorick et al reported levels of Endostatin in normals and
DS subjects. Levels for normal controls were 20.3 +/- 11.5
ng/ml with range of 4 to 40. For Down syndrome subjects,
the levels were 38.6 +/- 20.1 ng/ml with range of 6 to 76.
The sensitivity of the test kit was 2 ng/ml with typical
intra- and inter-assay variances of 10% or less.
Bevacizumab, a monoclonal antibody against VEGF, has
been available for several years and has made a major
impact especially in late stage colon cancer. It has only
been beneficial when combined with a conventional cyto-
toxic chemotherapy drug. As a monotherapy it has not
demonstrated value. No long term cures have been
claimed from use of Bevacizumab although the duration
of survival with metastatic colon cancer is markedly
improved. VEGF is a very important angiogenic pathway
in cancer. However there are many angiogenesis pathways
so shutting off one pathway may not prevent angiogenesis
from progressing via another pathway. Bevacizumab dis-
plays some dose limiting toxicity mainly hypertension.
Hypothesis – primary antiangiogenic therapy 
proposed
Data presented in a paper by Wu et al in 2003 suggest the
post cancer resection dynamics of VEGF and Endostatin in
the wound fluid and in plasma are quite distinct [35]. As
they report, mastectomies for a number of breast cancer
patients and female-to-male sex change cases were used to
measure angiogenesis inhibitors and promoters before
and after surgery. Endostatin and VEFG were measured in
plasma and wound fluid days 1 and 4 post surgery plus
Endostatin baseline was measured prior to surgery. VEGF
increased very significantly (9-fold) in wound fluid but
not in plasma. Endostatin decreased significantly and
temporarily by 20 – 30% in plasma but did not change in
wound fluid. The Endostatin decrease appeared at day sur-
gery+1 but then almost returned to presurgery levels by
surgery+4.
VEGF but not Endostatin is involved in wound healing
according to Wu et al data. Wu et al data on wound fluid
and plasma suggest that there are at least two important
and distinct pathways for angiogenesis in early stage
breast cancer. One pathway is for wound healing involv-
ing temporarily highly upregulated VEGF in the local
wound area and another pathway is for systemic stimula-
tion of tumor angiogenesis by temporarily down-regulat-
ing Endostatin. This interpretation of their data
apparently was not noticed by Wu et al.
This temporary dip in naturally occurring angiogenesis
inhibitors such as Endostatin is what produces the sur-
gery-induced angiogenesis. Sund et al mentions Throm-
bospondin and Tumstatin as endogenous suppressors of
angiogenesis in addition to Endostatin [32]. This suggests
that if the level of endogenous inhibitors such as Endosta-
tin, Angiostatin, Tumstatin, Thrombospondin or any
antiangiogenic acting protein from chromosome 21 such
as NC1 in plasma could be kept high at least for those few
critical days, it might prevent distant angiogenesis while
not interfering with wound healing. According to Errera et
al, Endostatin is a fragment of NC1 [36]. According to RohBMC Cancer 2009, 9:7 http://www.biomedcentral.com/1471-2407/9/7
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et al, Celecoxib and Indomethacin are also effective in pre-
venting wound healing associated tumor growth so those
drugs may be also considered in the list [37]. Celecoxib
was most beneficial when started 1 day before surgery in
animal models. There have been some suggestions that
Celecoxib may have some long term toxicity. The immu-
nostimulant Taurolidine also can prevent surgery induced
tumor growth according to Da Costa et al so that drug may
also be a candidate although the authors suggest this may
be a result of cells released following surgery [38].
We hypothesize that subtle interruption of the initiation
of angiogenesis within micrometastatic tumor deposits by
increasing endogenous Endostatin will prevent disease
progression as long as the level is retained but it must
begin before surgical resection. Taking a clue from the DS
situation where 1.3 to 1.8 times the level of Endostatin in
serum reportedly would prevent most solid tumors over
the life of the subject, an approximate value of Endostatin
to retain is at least 1.3 – 1.8 times the serum level in nor-
mal subjects. The amount of Endostatin to be added will
thus depend on the particular individual. Some may not
need any additional Endostatin beyond the first critical
few days post surgery. In addition, based on the Wu et al
data, the effect of surgery-induced angiogenesis is not tied
to removing any particular cancer but is a consequence of
general surgery. This strategy, shown in fig. 1, will apply to
any cancer patient, especially early stage, who has any sur-
gery.
While unlikely, long term use of Endostatin at the DS level
might have side effects. For example, since angiogenesis is
essential for follicle formation, it may induce castration in
premenopausal women. If that happened, improved sur-
vival for premenopausal women would result. Of course
that is not a bad result but it would complicate outcome
analysis. Such events need to be monitored in a trial.
Implications of the hypothesis
We have proposed a new method of therapy for early stage
breast cancer patients. It is designed to prevent angiogen-
esis and should keep all metastatic deposits microscopic
for as long as the therapy is continued without limit. No
drug resistance or toxicity is expected.
This therapy we suggest may or may not eradicate the
micrometastases even if given over a long time but it
could prevent growth beyond a mm or so indefinitely. The
advantages are important. First, adjuvant chemotherapy
and adjuvant hormone therapy might prove to be unnec-
essary since they seemingly serve to counteract surgery-
induced cell division and angiogenesis. Second, with rela-
tively long 2 year half-life, avascular dormancy is a natu-
rally very stable situation and would be far easier to
maintain long term with a low toxicity antiangiogenesis
inhibitor in comparison to eradicating metastases with
chemotherapy, radiation, surgery or antiangiogenic ther-
apy after they start to grow. Third, wound healing would
be unimpaired while an anti-VEGF drug such as Avastin
would very probably interfere with wound healing.
Fourth, this therapy could be continued for ensuing years
at appropriate elevated levels and may prevent future
relapses for all early stage breast cancer patients. Fifth, this
therapy takes full advantage of early detection and there
will be no paradoxical disadvantage to anyone diagnosed
early including premenopausal women. Sixth and most
important, mortality from breast cancer will be reduced.
Seventh, there should be no racial differences in outcome.
Eighth, this would be an ideal therapy for developing
countries where there is a minimum of health care funds
and supportive infrastructure such as medical specialists,
imaging equipment and well-equipped pathology labs.
Breast cancer is the most obvious, but this idea could be
applied to other cancers as well. Lung cancer, melanoma,
ovarian, cervical, prostate, and osteosarcoma [39] come to
mind. This therapy should work without need for adju-
vant chemotherapy, radiation, Herceptin for HER2 posi-
tive patients, or adjuvant hormone therapy. Perhaps even
removal of the primary tumor may be unnecessary for
some patients. The money saved by avoiding tests and not
needing those modalities would help offset the costs of
using Endostatin. While it is likely unreasonable to give
Endostatin to every healthy person as a preventative, it is
far more reasonable and economical to give it to every
cancer patient especially if this therapy prevents relapse
since that is when most of cancer care expenses occur.
Testing the hypothesis
Before we discuss a clinical test of this hypothesis, there
are a few other ways of testing that we may suggest. The
Wu et al study as well as our interpretation of their data
need verification. Perhaps autopsy studies of DS women
could look for the presence of ductal carcinoma in situ
(DCIS). If there is significant DCIS yet no breast cancer,
that might indicate carcinogenesis occurs normally in DS
but does not develop into breast cancer and perhaps inhi-
bition of angiogenesis is the reason. Can avascular dor-
mant micrometastases be observed and documented in
human breast cancer? Another test is with animal models.
Does a pre-established DS level of Endostatin prevent can-
cer from developing after inoculation with cancer cells in
some system that has some predisposition to dormancy
such as a breast model [40]?
The easiest way this idea could be tested in clinical situa-
tions would be to start with 50 or more consecutive high
risk, willing, Stage II breast cancer patients having 4 or
more positive lymph nodes. These would be randomized
half into controls given best conventional therapy andBMC Cancer 2009, 9:7 http://www.biomedcentral.com/1471-2407/9/7
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Comparison of conventional treatment and proposed primary antiangiogenic therapy for early stage breast cancer Figure 1
Comparison of conventional treatment and proposed primary antiangiogenic therapy for early stage breast 
cancer.
Newly diagnosed and confirmed early stage breast cancer
Conventional treatment Proposed treatment
Surgery to remove
primary tumor
Surgery to remove
primary tumor
Determine level of
endogenous Endostatin
and raise to level typical
of DS
Continue to monitor
Endostatin level and
keep at level typical of
DS
Adjuvant chemotherapy
and/or hormone therapy
Follow up and monitor
for relapse
Follow up and monitor
for relapseBMC Cancer 2009, 9:7 http://www.biomedcentral.com/1471-2407/9/7
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half test subjects given best conventional therapy plus
Endostatin at 1.8 times normal levels starting a few days
before surgery. This therapy would continue for 2–3 years
or longer, depending on results. Within a few years there
should be a significant difference in outcome if the idea is
correct. Afterwards, trials could be done to determine if
adjuvant therapy is needed at all.
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